GlobeNewswire: Chimerix, Inc. Contains the last 10 of 286 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:07:12ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/21/2850107/0/en/Chimerix-Appoints-Marc-D-Kozin-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=18971Chimerix Appoints Marc D. Kozin to Board of Directors2024-03-21T11:00:00Z<![CDATA[Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience]]>https://www.globenewswire.com/news-release/2024/02/29/2837830/0/en/Chimerix-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provides-Operational-Update.html?f=22&fvtc=4&fvtv=18971Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update2024-02-29T12:00:00Z<![CDATA[– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 –]]>https://www.globenewswire.com/news-release/2024/02/27/2835860/0/en/Chimerix-to-Present-at-TD-Cowen-44th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=18971Chimerix to Present at TD Cowen 44th Annual Health Care Conference2024-02-27T12:00:00Z<![CDATA[DURHAM, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a Targeted Oncology Panel at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 12:50 p.m. ET.]]>https://www.globenewswire.com/news-release/2024/02/22/2833506/0/en/Chimerix-to-Report-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provide-an-Operational-Update-on-February-29-2024.html?f=22&fvtc=4&fvtv=18971Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 20242024-02-22T12:00:00Z<![CDATA[DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, February 29, 2024 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2023, and to provide a business overview.]]>https://www.globenewswire.com/news-release/2023/12/29/2802020/0/en/Chimerix-Appoints-Lisa-Decker-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=18971Chimerix Appoints Lisa Decker to Board of Directors2023-12-29T12:00:00Z<![CDATA[Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience]]>https://www.globenewswire.com/news-release/2023/12/04/2789873/0/en/Chimerix-Promotes-Michelle-LaSpaluto-to-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=18971Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer2023-12-04T12:00:00Z<![CDATA[Proven Leader Brings More Than 25 Years of Financial Experience Proven Leader Brings More Than 25 Years of Financial Experience]]>https://www.globenewswire.com/news-release/2023/11/24/2785549/0/en/Chimerix-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=18971Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2023-11-24T12:00:00Z<![CDATA[DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified stock options to purchase 150,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment agreement in accordance with Nasdaq Listing rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2023/11/16/2781700/0/en/Chimerix-Strengthens-Executive-Leadership-Team-with-Appointment-of-Thomas-Riga-as-Chief-Operating-and-Commercial-Officer.html?f=22&fvtc=4&fvtv=18971Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer2023-11-16T12:00:00Z<![CDATA[Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development]]>https://www.globenewswire.com/news-release/2023/11/02/2772085/0/en/Chimerix-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Operational-Update.html?f=22&fvtc=4&fvtv=18971Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update2023-11-02T11:00:00Z<![CDATA[– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 –]]>https://www.globenewswire.com/news-release/2023/10/26/2767333/0/en/Chimerix-to-Report-Third-Quarter-2023-Financial-Results-and-Provide-an-Operational-Update-on-November-2-2023.html?f=22&fvtc=4&fvtv=18971Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 20232023-10-26T11:00:00Z<![CDATA[DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 2, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business overview.]]>